Safety and Effectiveness of PEG-Intron in HIV-Infected Patients

June 23, 2005 updated by: Schering-Plough

Antiviral Activity and Tolerability of PEG-Intron in HIV-Infected Subjects Failing HAART

The purpose of this study is to see if it is effective to give PEG-Intron (PEG-IFN) to HIV-infected patients who are not doing well with their current anti-HIV drug combination (HAART).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

At entry, patients undergo HIV genotypic/phenotypic analysis. Patients continue their current antiretroviral regimen but are randomized to receive one of four doses of PEG-IFN or PEG-IFN placebo administered subcutaneously once per week until results of HIV genotyping/phenotyping are available (approximately 4 weeks). Patients who respond with a 0.5 log or greater decrease in HIV RNA at Week 4 have optimized HAART added to their ongoing PEG-IFN regimen and are followed for 24 weeks in an observational study.

Study Type

Interventional

Enrollment

250

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • San Juan, Puerto Rico, 009265800
        • San Juan Vamc
    • California
      • Berkeley, California, United States, 94705
        • East Bay AIDS Ctr
    • District of Columbia
      • Washington, District of Columbia, United States, 200091104
        • Dupont Circle Physicians Group
      • Washington, District of Columbia, United States, 20007
        • Georgetown Univ Med Ctr
    • Florida
      • Altamonte Springs, Florida, United States, 32701
        • IDC Research Initiative
      • Jacksonville, Florida, United States, 32206
        • Duval County Health Department
      • Miami, Florida, United States, 33136
        • Univ of Miami School of Medicine
      • Sarasota, Florida, United States, 34239
        • Infectious Diseases Associates
    • Georgia
      • Atlanta, Georgia, United States, 30339
        • Piedmont Physicians at Vinings
    • Illinois
      • Chicago, Illinois, United States, 60657
        • TRIAD Health Practice
    • Maryland
      • Baltimore, Maryland, United States, 212011192
        • Univ of Maryland Institute of Human Virology
    • Massachusetts
      • Boston, Massachusetts, United States, 02111
        • New England Med Ctr / Div of Geo Med & Infect Disease
    • Minnesota
      • St. Paul, Minnesota, United States, 55101
        • Regions Hosp
    • Missouri
      • St. Louis, Missouri, United States, 63110
        • Washington Univ
    • New Jersey
      • Camden, New Jersey, United States, 08103
        • Southwestern New Jersey AIDS Clinical Trials
      • East Orange, New Jersey, United States, 07018
        • East Orange Veterans Administration Med Ctr
    • New York
      • New York, New York, United States, 10003
        • Beth Israel Med Ctr
    • Ohio
      • Cleveland, Ohio, United States, 44106
        • Univ Hosps of Cleveland
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Philadelphia FIGHT
      • Philadelphia, Pennsylvania, United States, 19102
        • MCP Hahnemann Univ
    • Texas
      • Dallas, Texas, United States, 75235
        • Amelia Ct Clinic
      • Houston, Texas, United States, 77004
        • Joseph C Gathe

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 second and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

Patients may be eligible for this study if they:

  • Have HIV levels of more than 2000 copies/ml.
  • Have failed their current HAART (had a significant increase in their HIV levels with HAART).
  • Have a CD4 cell count greater than 200 cells/microL.
  • Have had more than 6 months of HAART.
  • Have been on their current HAART for at least 6 weeks.
  • Agree to use an effective method of birth control during the study.

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have a history of a serious mental disorder.
  • Are allergic to interferons.
  • Are pregnant or breast-feeding.
  • Are taking certain medications such as ribavirin, hydroxyurea, and ganciclovir.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2000

Study Completion

September 1, 2000

Study Registration Dates

First Submitted

March 29, 2000

First Submitted That Met QC Criteria

August 30, 2001

First Posted (Estimate)

August 31, 2001

Study Record Updates

Last Update Posted (Estimate)

June 24, 2005

Last Update Submitted That Met QC Criteria

June 23, 2005

Last Verified

August 1, 2000

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV Infections

Clinical Trials on Peginterferon alfa-2b

3
Subscribe